Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Neurosurgery, University of California Irvine, Orange, California, USA.
World Neurosurg. 2019 Jul;127:e193-e201. doi: 10.1016/j.wneu.2019.02.204. Epub 2019 Mar 13.
Flow diversion is increasingly used for off-label treatments of distal circulation aneurysms. Reports of use in sub-2.0-mm vessels are scant.
A prospectively collected, institutional review board-approved cerebral aneurysm database was reviewed to identify patients who underwent flow diversion with a 2.5-mm diameter Pipeline embolization device.
Sixty-seven aneurysms were treated in 67 procedures (66 [99%] successful, 64 [96%] single device, 2 [3%] with 2 devices) in 57 patients. Average age was 56 years and 60% were female. Aneurysm location was 51 (76%) anterior cerebral artery, 14 (21%) middle cerebral artery, and 2 (3%) posterior cerebral artery. Aneurysm size was 4.1 ± 3.0 mm (1-20 mm). Safety outcomes included 3 major strokes (4.5%) resulting in permanent neurologic deficit (modified Rankin Scale score 6,4,4), including 1 mortality (1.5%). Acute stent thrombosis was observed intraprocedurally or within 24 hours of each stroke. There were 2 small-volume (<10 cm, 40 cm) dependent intracerebral hemorrhage (3.0%) that resolved without permanent neurologic deficit. For effectiveness, 71% of patients underwent follow-up angiography. Complete occlusion was achieved by 88% at 6 months, 86% at 12 months, and 89% at last follow-up. A slight vessel diameter reduction was apparent on average 6.9 months after the procedure, which was statistically significant at the proximal (P = 0.001) but not distal (P = 0.317) device end. Preoperative average parent vessel diameter was 1.9 mm proximally (range, 1.1-2.6 mm) and 1.7 mm distally (range, 1.0-2.3 mm) of the Pipeline embolization device. Follow-up average vessel diameter was 1.7 mm proximally (range, 0.7-2.4 mm) and 1.6 mm distally (range, 0.6-2.1 mm). Flow delay associated with vessel diameter reduction occurred once. There were no cases of asymptomatic vessel occlusion.
Flow diversion can be safe and effective for aneurysms originating from vessels <2.0 mm in diameter. Heightened vigilance for the prevention and management of acute stent and vessel thrombosis is warranted in these cases.
血流导向装置越来越多地用于治疗远端循环动脉瘤的超适应证治疗。关于在直径<2.0mm 的血管中使用的报告很少。
对前瞻性收集的机构审查委员会批准的脑动脉瘤数据库进行回顾,以确定接受 2.5mm 直径 Pipeline 栓塞装置治疗的患者。
67 例患者 67 例次(66 例[99%]成功,64 例[96%]单次使用装置,2 例[3%]使用 2 个装置)接受了治疗。平均年龄为 56 岁,60%为女性。动脉瘤位置为 51 例(76%)前交通动脉,14 例(21%)大脑中动脉,2 例(3%)后交通动脉。动脉瘤大小为 4.1±3.0mm(1-20mm)。安全性结果包括 3 例(4.5%)大卒中和永久性神经功能缺损(改良 Rankin 量表评分 6、4、4),其中 1 例(1.5%)死亡。术中或每例卒后 24 小时内观察到急性支架内血栓形成。2 例小体积(<10cm,40cm)依赖性颅内出血(3.0%)未遗留永久性神经功能缺损。对于有效性,71%的患者进行了随访血管造影。6 个月时完全闭塞率为 88%,12 个月时为 86%,最后一次随访时为 89%。术后平均 6.9 个月时,支架近端(P=0.001)但支架远端(P=0.317)血管直径缩小,差异有统计学意义。术前近端母血管直径为 1.9mm(范围,1.1-2.6mm),Pipeline 栓塞装置近端为 1.7mm(范围,1.0-2.3mm)。随访时近端血管直径为 1.7mm(范围,0.7-2.4mm),远端血管直径为 1.6mm(范围,0.6-2.1mm)。发生一次与血管直径缩小相关的血流延迟。无症状血管闭塞的病例均未发生。
对于直径<2.0mm 的血管起源的动脉瘤,血流导向装置治疗是安全有效的。在这些情况下,需要警惕急性支架内和血管内血栓形成的预防和管理。